HFpEF: The Heart Failure Diagnosis Men Most Often Receive Too Late

When most men think about heart failure, they picture a heart that is too weak to pump. They imagine a reduced ejection fraction, a dilated chamber, a weak squeeze. They picture the type of heart failure that is easy to diagnose and easy to understand.

There is another form that does not fit this picture, and it is increasingly common in men over 50. Heart failure with preserved ejection fraction, known as HFpEF (pronounced “H-F-pef”), is a condition in which the heart’s pumping function looks completely normal on an echocardiogram but the heart has become stiff, is unable to fill properly, and is failing the patient just as surely as a weakly contracting one.

This condition is frequently missed, frequently delayed in diagnosis, and frequently misattributed to deconditioning, obesity, or simply getting older. Understanding what it is, how it develops, how it differs from the more familiar form of heart failure, and how it is diagnosed is essential for any man who is navigating a combination of hypertension, metabolic risk factors, and unexplained exercise intolerance.

The Two Faces of Heart Failure

Heart failure is not a single disease. It is a clinical syndrome defined by the heart’s inability to deliver sufficient blood to meet the body’s metabolic needs, or to do so only at the cost of elevated filling pressures that produce congestion.

Historically, the primary form recognized and studied was heart failure with reduced ejection fraction, now called HFrEF. In HFrEF, the left ventricle is weakly contracting. The ejection fraction (EF), which measures the percentage of blood the left ventricle ejects with each beat, falls below 40 percent. A normal ejection fraction is typically between 55 and 70 percent. The heart in HFrEF is often dilated, the walls may be thin, and the problem is clearly one of systolic dysfunction: the heart cannot squeeze well.

HFpEF is different. The ejection fraction is preserved, meaning it is 50 percent or higher. The heart squeezes normally. The problem is in relaxation and filling. The left ventricle has become stiff, a state called diastolic dysfunction. During diastole, the period when the heart is supposed to relax and fill with blood from the lungs, a stiff ventricle resists filling. It requires higher pressures to accept blood. Those higher pressures back up into the pulmonary circulation, causing fluid to accumulate in the lungs and producing the breathlessness that is the hallmark of heart failure symptoms.

Because the ejection fraction is normal, and because the squeeze looks fine on an echocardiogram, the diagnosis is frequently overlooked. Breathlessness is attributed to obesity. Reduced exercise capacity is attributed to deconditioning or age. The elevated filling pressures are not apparent on a resting echocardiogram in early disease. The patient and sometimes the physician both miss what is happening.

Why HFpEF Is Specifically a Men’s Health Issue

HFpEF affects both men and women, but the epidemiology, risk drivers, and presentation differ between sexes. In women, HFpEF tends to be driven more by hypertension and microvascular dysfunction and tends to present at older ages. In men, the condition has a distinct risk profile shaped by decades of metabolic exposure.

The four major contributors to HFpEF in men are hypertension, obesity, type 2 diabetes or insulin resistance, and obstructive sleep apnea. These are not coincidental associations; they are mechanistically linked to the pathology. Each of these conditions, and particularly the combination of them, drives the cardiometabolic inflammation, oxidative stress, and fibrosis that ultimately stiffen the myocardium.

Data from the I-Preserve trial, the CHARM-Preserved trial, and epidemiological studies from the Olmsted County cohort have documented that HFpEF now accounts for more than 50 percent of all heart failure cases in many populations, and that prevalence is rising in parallel with obesity and diabetes rates. In men specifically, obesity-related HFpEF is an increasingly recognized phenotype, sometimes called the obese HFpEF phenotype, characterized by massive pericardial fat accumulation, inflammation, and elevated filling pressures even at rest in more advanced cases.

The population of men who are at highest risk for HFpEF is therefore not elderly and frail but often middle-aged, metabolically burdened, and functionally impaired in ways they may attribute to lifestyle choices rather than a cardiac diagnosis. This delayed attribution is one of the principal reasons the condition is underdiagnosed.

What Happens to the Heart in HFpEF

To understand HFpEF, it helps to understand what normal cardiac relaxation looks like and what disrupts it.

In a healthy left ventricle, contraction and relaxation are rapid and energy-efficient. Calcium cycles in and out of cardiac muscle cells with each beat. After contraction, the cell actively removes calcium, allowing the myofilaments to release and the muscle to relax. This active relaxation process is energy-dependent and is impaired by ischemia, hypertrophy, and metabolic stress.

Over years of hypertension, the left ventricle adapts to sustained high afterload by thickening its walls, a process called concentric hypertrophy. The thickened wall generates more force to eject blood against elevated pressure, but it also becomes stiffer. The chamber becomes smaller relative to wall thickness. When it needs to fill with blood, it fills more slowly and at higher pressure.

The extracellular matrix of the myocardium also remodels. Fibrosis, driven by inflammation and mechanical stress, deposits collagen between cardiac muscle cells. Collagen is stiff. As fibrosis accumulates over time, the ventricle loses its compliance. It can still contract normally because the muscle cells themselves are still functioning, but the chamber as a whole resists filling.

Diabetes and obesity add another layer. Insulin resistance alters the energetics of cardiac muscle, shifting metabolism toward fatty acid oxidation and producing mitochondrial dysfunction. Visceral adiposity drives systemic inflammation and deposits fat within and around the myocardium (epicardial and pericardial fat). These changes impair relaxation independently of hypertension, which explains why men with well-controlled blood pressure but significant metabolic syndrome can still develop HFpEF.

Sleep apnea contributes through intermittent hypoxia, sympathetic activation, and repetitive surges in intrathoracic pressure during apneic episodes, all of which promote left ventricular hypertrophy and diastolic dysfunction. Men with moderate to severe untreated obstructive sleep apnea have a substantially elevated prevalence of echocardiographic diastolic dysfunction, even before overt HFpEF develops.

How HFpEF Presents in Men

The symptoms of HFpEF overlap considerably with HFrEF: breathlessness with exertion, fatigue, reduced exercise tolerance, and in more advanced disease, fluid retention with ankle swelling and orthopnea (breathlessness when lying flat).

What distinguishes HFpEF presentation in men is the typical backdrop: a history of longstanding hypertension, metabolic risk factors, possibly undiagnosed sleep apnea, a BMI in the overweight or obese range, and a trajectory of progressive exercise intolerance that has developed slowly enough to be normalized.

The breathlessness in HFpEF is frequently exertional in early stages. Men describe being unable to climb stairs without stopping, or finding activities that were previously easy now require disproportionate effort. This exertional breathlessness can be falsely attributed to obesity or deconditioning. The critical distinction is that it is out of proportion to what the level of fitness or body weight would predict, and it does not improve with exercise training alone the way deconditioning would.

Another characteristic of HFpEF presentation in men is the stress test paradox. A resting echocardiogram may look completely normal. Ejection fraction is preserved. Diastolic parameters may be within normal limits at rest. The man may be told his heart looks fine. But during exertion, filling pressures rise steeply because the stiff ventricle cannot accommodate the increased venous return of exercise. This is why exercise-induced breathlessness can be the dominant and sometimes only symptom for years before a resting evaluation reveals obvious abnormality.

Diagnosing HFpEF: Why It Is Harder Than It Looks

The diagnosis of HFpEF is more complex than the diagnosis of HFrEF. In HFrEF, a reduced ejection fraction on echocardiogram plus symptoms is generally sufficient to make the diagnosis. In HFpEF, the ejection fraction is by definition normal, so the diagnosis requires demonstrating diastolic dysfunction and elevated filling pressures.

Echocardiography remains the cornerstone of initial evaluation. Several parameters of diastolic function can be measured: tissue Doppler imaging of the mitral annulus (E/e’ ratio), left atrial size and volume index, peak tricuspid regurgitation velocity, and mitral inflow patterns. An elevated E/e’ ratio (specifically above 14), an enlarged left atrial volume index (above 34 mL/m2), or evidence of elevated right heart pressures on Doppler can each suggest diastolic dysfunction and elevated filling pressures.

However, these parameters have important limitations. In early or mild disease, resting echocardiographic parameters can appear normal even when the patient has HFpEF. Left atrial enlargement, while a sensitive marker of chronic elevated filling pressures, takes time to develop and may not be present at initial evaluation.

Natriuretic peptides, specifically BNP (B-type natriuretic peptide) and NT-proBNP, are secreted by heart muscle cells in response to stretch and elevated wall stress. They are elevated in the majority of patients with HFpEF at the time of symptomatic presentation. However, natriuretic peptide levels are complex to interpret. They are lower in obese patients than in non-obese patients with equivalent heart failure severity (the obesity natriuretic peptide paradox), which means that in the obese HFpEF phenotype, BNP may fall within normal limits even in the presence of significant disease. They are also elevated by atrial fibrillation, renal insufficiency, and pulmonary disease, which can complicate interpretation.

Exercise stress echocardiography, or diastolic stress testing, is an increasingly used approach for diagnosing HFpEF in patients with preserved ejection fraction and unexplained exertional symptoms. By imaging the heart during exercise, cardiologists can observe the rise in filling pressures with exertion that defines HFpEF hemodynamically, even when resting parameters are normal. An E/e’ ratio that rises substantially with exertion (above 15 at peak exercise) is considered diagnostic of exercise-induced elevated filling pressures consistent with HFpEF.

Right heart catheterization remains the gold standard for directly measuring filling pressures and remains important in cases where non-invasive testing is inconclusive and the diagnosis is clinically critical.

A clinical scoring tool, the HFA-PEFF score, has been developed to integrate symptoms, clinical variables, echocardiographic parameters, and biomarkers into a structured diagnostic pathway. Your cardiologist may use this or similar frameworks to structure the evaluation.

How HFpEF Differs From HFrEF in Practice

Understanding the differences between HFpEF and HFrEF matters for men because it shapes the management approach and the prognosis.

In HFrEF, there is a strong evidence base supporting specific therapeutic agents that reduce mortality. Several drug classes have demonstrated survival benefit in HFrEF through large randomized controlled trials. These agents are the foundation of HFrEF management.

In HFpEF, the picture has historically been more complicated. The trials that demonstrated mortality benefit in HFrEF did not show the same benefit in HFpEF populations. For many years, management of HFpEF focused primarily on symptom control, diuresis for congestion, and aggressive management of underlying contributing conditions (hypertension, diabetes, sleep apnea, atrial fibrillation) rather than on heart-failure-specific agents with proven survival benefit.

That picture has been evolving. The EMPEROR-Preserved and DELIVER trials demonstrated that SGLT2 inhibitors, a class of agents originally developed for diabetes, reduce hospitalizations for heart failure in patients with HFpEF and mildly reduced ejection fraction. This represented the first evidence of a drug class with meaningful benefit in this population. Discuss with your cardiologist which agents are appropriate for your specific situation, given the evolving evidence base and your other medical conditions.

The mortality improvement observed in HFrEF trials has not been replicated in HFpEF. This reflects the fundamentally different pathophysiology. HFpEF is not simply HFrEF with a better ejection fraction; it is a distinct syndrome with different underlying biology, different risk factor contributions, and a different therapeutic landscape.

The Role of Comorbidity Management

Because HFpEF is driven so significantly by comorbid conditions, managing those conditions is central to the management approach for HFpEF. This is different from HFrEF, where heart-failure-specific pharmacotherapy dominates the evidence.

Hypertension management is critical. Elevated blood pressure is both a primary driver of the left ventricular hypertrophy and fibrosis that underlie diastolic dysfunction and a source of ongoing hemodynamic stress that worsens symptoms. Blood pressure control is a cornerstone of HFpEF management.

Obesity and metabolic syndrome management has growing evidence for benefit. Weight reduction in obese men with HFpEF has been shown to reduce filling pressures, improve exercise capacity, and reduce natriuretic peptide levels. The pathophysiology connecting visceral adiposity to HFpEF provides a mechanistic rationale for the clinical benefit of weight management.

Obstructive sleep apnea treatment is important both for blood pressure control and for reducing the repetitive hemodynamic and hypoxic stress on the left ventricle. Men with HFpEF should be evaluated for sleep apnea if not already diagnosed, and treatment should be improved.

Atrial fibrillation is both a consequence and an aggravator of HFpEF. The stiff, high-pressure left atrium that develops in HFpEF is prone to atrial fibrillation. Conversely, atrial fibrillation worsens HFpEF symptoms by eliminating the atrial kick that contributes to ventricular filling in a stiff chamber. Rate or rhythm control of atrial fibrillation is therefore an important therapeutic consideration in men with HFpEF and concurrent atrial fibrillation.

Diabetes management using agents with cardiac benefit, particularly SGLT2 inhibitors and GLP-1 receptor agonists, has increasing evidence supporting their use in this population on the basis of both metabolic benefit and potential direct cardiac effects.

Exercise in HFpEF: Counterintuitive but Critical

One finding that surprises many men with HFpEF is that supervised exercise training has some of the strongest evidence for symptomatic benefit. Given that the main symptom is breathlessness with exertion, it seems paradoxical that exercise should be part of management.

The explanation lies in the peripheral adaptations to exercise training: improvements in skeletal muscle oxygen extraction, reduced ventilatory inefficiency, and improved autonomic tone. These adaptations reduce the cardiac demand for any given workload, effectively raising the threshold at which symptoms appear. Exercise training also reduces sympathetic tone, improves metabolic fitness, and supports weight management.

The ExTraMATCH II meta-analysis and individual trials in HFpEF populations have documented improvements in peak oxygen consumption (VO2 peak) and quality of life with supervised exercise training. The magnitude of improvement is meaningful enough to be clinically significant for most patients. Your cardiologist may refer you to a cardiac rehabilitation program, which provides supervised, medically appropriate exercise in the context of your overall cardiac status.

This does not mean unsupervised, high-intensity exercise at home. It means structured, progressive exercise conducted with appropriate monitoring, especially early in the process when your safe functional capacity and cardiac response to exertion have been characterized.

Getting the Diagnosis: A Practical Path

For men who recognize themselves in this picture, the path to diagnosis starts with a candid conversation with a physician about the full symptom picture: the exertional breathlessness, the pace of functional decline, the longstanding hypertension or metabolic comorbidities, and the failure of simple lifestyle interventions to produce expected improvement.

A thorough evaluation typically begins with an echocardiogram and natriuretic peptide measurement. If initial testing is inconclusive but symptoms are persistent and unexplained, your cardiologist may consider exercise echocardiography, cardiopulmonary exercise testing (CPET), or referral to a specialist in heart failure with specific experience in HFpEF.

The important message is that a normal ejection fraction does not mean the heart is fine. It means the squeeze is preserved. The stiffness, the elevated filling pressures, and the resulting symptoms require a different evaluation lens, and that lens is now available in clinical practice.

Frequently Asked Questions

Q: My echocardiogram showed a normal ejection fraction. My cardiologist said my heart looks fine. Why am I still so breathless? A: A normal ejection fraction confirms that your heart contracts normally but does not assess diastolic function, filling pressures, or the cardiac response to exertion. If you have risk factors for HFpEF (hypertension, obesity, diabetes, sleep apnea) and unexplained exertional breathlessness, asking your cardiologist specifically about diastolic dysfunction and whether exercise stress echocardiography or natriuretic peptide testing is appropriate for your situation is a reasonable next step.

Q: Is HFpEF reversible? A: HFpEF is not simply reversed, but it can improve. Men who achieve significant weight loss, good blood pressure control, effective sleep apnea treatment, and improved metabolic status have shown improvements in diastolic function parameters, natriuretic peptide levels, and exercise capacity in clinical studies. The fibrosis and hypertrophy that accumulate over decades do not disappear quickly, but the hemodynamic burden that drives them forward can be reduced meaningfully with comprehensive risk factor management.

Q: How is HFpEF different from just being out of shape? A: The symptoms can overlap, but key differences emerge on objective testing. Deconditioning typically improves substantially with a structured exercise program over weeks to months. HFpEF produces breathlessness that is out of proportion to the degree of deconditioning, is associated with elevated filling pressures on hemodynamic testing, and involves structural or functional cardiac changes on echocardiography. Cardiopulmonary exercise testing can help distinguish reduced cardiac reserve from reduced peripheral fitness, which is why your cardiologist may order this test when the cause of exercise intolerance is uncertain.

Q: My father had heart failure and was told his heart was “weak.” Is my HFpEF the same condition? A: Almost certainly not. Your father likely had heart failure with reduced ejection fraction (HFrEF), the form in which the heart weakly contracts. HFpEF is a distinct syndrome with different underlying biology, different echocardiographic appearance, and a substantially different management approach. The two conditions share the name “heart failure” because both result in the clinical syndrome of breathlessness, congestion, and reduced exercise tolerance, but their causes and treatments differ meaningfully.

Q: Should men with risk factors like hypertension and obesity be screened for HFpEF before symptoms develop? A: Routine screening for asymptomatic diastolic dysfunction in unselected men is not currently recommended by major guidelines. However, men with multiple risk factors (longstanding hypertension, obesity, diabetes, sleep apnea) who develop unexplained exertional symptoms warrant prompt evaluation rather than watchful waiting. Early identification of diastolic dysfunction before it progresses to overt HFpEF, through echocardiographic evaluation in high-risk symptomatic individuals, offers the opportunity to intervene on contributing conditions while the disease is still at a more reversible stage.

The Signal Check is fifteen questions mapping the male cardiovascular risk pattern, including the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.